Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82


Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Montalban X, Belachew S, Wolinsky JS.

N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available.


Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Hauser SL, Belachew S, Kappos L.

N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available.


Healthcare Professionals' Awareness, Knowledge, Attitudes, Perceptions and Beliefs about Ebola at Gondar University Hospital, Northwest Ethiopia: A Cross-sectional Study.

Abebe TB, Bhagavathula AS, Tefera YG, Ahmad A, Khan MU, Belachew SA, Brown B, Abegaz TM.

J Public Health Afr. 2016 Dec 31;7(2):570. doi: 10.4081/jphia.2016.570. eCollection 2016 Dec 31.


Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CA, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.


Recreational Use of Phosphodiesterase 5 Inhibitors and Its Associated Factors among Undergraduate Male Students in an Ethiopian University: A Cross-Sectional Study.

Gebreyohannes EA, Bhagavathula AS, Gebresillassie BM, Tefera YG, Belachew SA, Erku DA.

World J Mens Health. 2016 Dec;34(3):186-193. doi: 10.5534/wjmh.2016.34.3.186. Epub 2016 Dec 22.


Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators..

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.


Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators..

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.


Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study.

Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM.

Drug Healthc Patient Saf. 2016 Dec 8;8:83-90. eCollection 2016.


Preferred information sources and needs of cancer patients on disease symptoms and management: a cross-sectional study.

Mekuria AB, Erku DA, Belachew SA.

Patient Prefer Adherence. 2016 Sep 29;10:1991-1997. eCollection 2016.


Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study.

Getachew H, Bhagavathula AS, Abebe TB, Belachew SA.

Clin Interv Aging. 2016 Jun 20;11:819-27. doi: 10.2147/CIA.S107394. eCollection 2016.


Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.


Management of children's acute diarrhea by community pharmacies in five towns of Ethiopia: simulated client case study.

Abegaz TM, Belachew SA, Abebe TB, Gebresilassie BM, Teni FS, Woldie HG.

Ther Clin Risk Manag. 2016 Apr 5;12:515-26. doi: 10.2147/TCRM.S98474. eCollection 2016.


Evaluation of preceptors and skills achievement by clinical pharmacy clerkship students during their clinical rotations at University of Gondar, Ethiopia.

Belachew SA, Abegaz TM, Bhagavathula AS, Getachew H, Tefera YG.

Adv Med Educ Pract. 2016 Mar 29;7:187-96. doi: 10.2147/AMEP.S95820. eCollection 2016.


Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).

Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S; Tysabri® Observational Program (TOP) Investigators..

PLoS One. 2016 Jan 15;11(1):e0144834. doi: 10.1371/journal.pone.0144834. eCollection 2016.


Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H.

Ann Clin Transl Neurol. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27.


Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.

Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.

Mult Scler Relat Disord. 2014 Nov;3(6):705-11. doi: 10.1016/j.msard.2014.08.005. Epub 2014 Sep 6.


Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.

Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D.

Eur J Neurol. 2015 Mar;22(3):570-7. doi: 10.1111/ene.12618. Epub 2014 Dec 15.


Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.

Ann Neurol. 2014 Dec;76(6):802-12. doi: 10.1002/ana.24286. Epub 2014 Oct 24.


Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators..

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14.


More on JC viremia in natalizumab-treated patients with multiple sclerosis.

Subramanyam M, Belachew S, Compton T.

N Engl J Med. 2013 Sep 26;369(13):1279-80. doi: 10.1056/NEJMc1308784#SA1. No abstract available.


Supplemental Content

Loading ...
Support Center